299 related articles for article (PubMed ID: 29080212)
1. Targeting inflammation to reduce cardiovascular disease risk.
Maffia P; Cirino G
Br J Pharmacol; 2017 Nov; 174(22):3895-3897. PubMed ID: 29080212
[TBL] [Abstract][Full Text] [Related]
2. Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect?
Welsh P; Grassia G; Botha S; Sattar N; Maffia P
Br J Pharmacol; 2017 Nov; 174(22):3898-3913. PubMed ID: 28409825
[TBL] [Abstract][Full Text] [Related]
3. WNT signalling: mechanisms and therapeutic opportunities.
Schulte G; Bryja V
Br J Pharmacol; 2017 Dec; 174(24):4543-4546. PubMed ID: 29235106
[TBL] [Abstract][Full Text] [Related]
4. Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism.
Iqbal F; Baker WS; Khan MI; Thukuntla S; McKinney KH; Abate N; Tuvdendorj D
Br J Pharmacol; 2017 Nov; 174(22):3986-4006. PubMed ID: 28326542
[TBL] [Abstract][Full Text] [Related]
5. Molecular pharmacology of G protein-coupled receptors.
Summers RJ
Br J Pharmacol; 2016 Oct; 173(20):2931-3. PubMed ID: 27682321
[TBL] [Abstract][Full Text] [Related]
6. Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials.
Catapano AL; Pirillo A; Norata GD
Br J Pharmacol; 2017 Nov; 174(22):3973-3985. PubMed ID: 28369752
[TBL] [Abstract][Full Text] [Related]
7. Unravelling the adiponectin paradox: novel roles of adiponectin in the regulation of cardiovascular disease.
Woodward L; Akoumianakis I; Antoniades C
Br J Pharmacol; 2017 Nov; 174(22):4007-4020. PubMed ID: 27629236
[TBL] [Abstract][Full Text] [Related]
8. Nitric oxide and hydrogen sulfide: the gasotransmitter paradigm of the vascular system.
Cirino G; Vellecco V; Bucci M
Br J Pharmacol; 2017 Nov; 174(22):4021-4031. PubMed ID: 28407204
[TBL] [Abstract][Full Text] [Related]
9. Anti-atherosclerotic effect of the angiotensin 1-7 mimetic AVE0991 is mediated by inhibition of perivascular and plaque inflammation in early atherosclerosis.
Skiba DS; Nosalski R; Mikolajczyk TP; Siedlinski M; Rios FJ; Montezano AC; Jawien J; Olszanecki R; Korbut R; Czesnikiewicz-Guzik M; Touyz RM; Guzik TJ
Br J Pharmacol; 2017 Nov; 174(22):4055-4069. PubMed ID: 27935022
[TBL] [Abstract][Full Text] [Related]
10. Emerging areas of opioid pharmacology.
Kelly E; Henderson G; Bailey CP
Br J Pharmacol; 2018 Jul; 175(14):2715-2716. PubMed ID: 29939423
[TBL] [Abstract][Full Text] [Related]
11. T-cell immunity in myocardial inflammation: pathogenic role and therapeutic manipulation.
Stephenson E; Savvatis K; Mohiddin SA; Marelli-Berg FM
Br J Pharmacol; 2017 Nov; 174(22):3914-3925. PubMed ID: 27590129
[TBL] [Abstract][Full Text] [Related]
12. Immunity and hypertension: New targets to lighten the pressure.
Vinh A; Drummond GR; Sobey CG
Br J Pharmacol; 2019 Jun; 176(12):1813-1817. PubMed ID: 31127619
[TBL] [Abstract][Full Text] [Related]
13. Pharmacology of cognition: a panacea for neuropsychiatric disease?
Bailey SJ; Neill JC; Moran PM
Br J Pharmacol; 2017 Oct; 174(19):3133-3135. PubMed ID: 28901012
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology of oxidative stress: translational opportunities.
Daiber A; Di Lisa F; Ferdinandy P
Br J Pharmacol; 2017 Jun; 174(12):1511-1513. PubMed ID: 28555779
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of microsomal PGE synthase-1 reduces human vascular tone by increasing PGI
Ozen G; Gomez I; Daci A; Deschildre C; Boubaya L; Teskin O; Uydeş-Doğan BS; Jakobsson PJ; Longrois D; Topal G; Norel X
Br J Pharmacol; 2017 Nov; 174(22):4087-4098. PubMed ID: 28675448
[TBL] [Abstract][Full Text] [Related]
16. Readapting the adaptive immune response - therapeutic strategies for atherosclerosis.
Sage AP; Mallat Z
Br J Pharmacol; 2017 Nov; 174(22):3926-3939. PubMed ID: 28052311
[TBL] [Abstract][Full Text] [Related]
17. Aspirin-triggered lipoxin A4 inhibits atherosclerosis progression in apolipoprotein E
Petri MH; Laguna-Fernandez A; Arnardottir H; Wheelock CE; Perretti M; Hansson GK; Bäck M
Br J Pharmacol; 2017 Nov; 174(22):4043-4054. PubMed ID: 28071789
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic lymphocytes and atherosclerosis: significance, mechanisms and therapeutic challenges.
Kyaw T; Peter K; Li Y; Tipping P; Toh BH; Bobik A
Br J Pharmacol; 2017 Nov; 174(22):3956-3972. PubMed ID: 28471481
[TBL] [Abstract][Full Text] [Related]
19. Targeting vascular (endothelial) dysfunction.
Daiber A; Steven S; Weber A; Shuvaev VV; Muzykantov VR; Laher I; Li H; Lamas S; Münzel T
Br J Pharmacol; 2017 Jun; 174(12):1591-1619. PubMed ID: 27187006
[TBL] [Abstract][Full Text] [Related]
20. Principles of pharmacological research of nutraceuticals.
Andrew R; Izzo AA
Br J Pharmacol; 2017 Jun; 174(11):1177-1194. PubMed ID: 28500635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
